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MACULAR PIGMENT OPTICAL DENSITY
IS LOWER IN TYPE 2 DIABETES,
COMPARED WITH TYPE 1 DIABETES AND
NORMAL CONTROLSAU1
GRAINNE SCANLON, MPHIL,* PAUL CONNELL, MD,† MATTHEW RATZLAFF, BSC,‡
BRITTANY FOERG, BSC,‡ DANIEL MCCARTNEY, PHD,* AUDREY MURPHY, BSC,†
KAREN O’CONNOR, BSC,† JAMES LOUGHMAN, PHD*¶
Purpose: This study was designed to investigate the optical density of macular pigment
in Type 1 and Type 2 diabetes subjects relative to normal controls.
Methods: One hundred and fifty subjects were recruited to the study and divided into
one of the three study groups on the basis of their health status, as follows: Group 1:
Healthy controls; Group 2: Type 1 diabetes; Group 3: Type 2 diabetes. Macular Pigment
Optical Density, at 0.5° of retinal eccentricity, was measured using customized heterochro-
matic flicker photometry. Dietary intake of macular carotenoids was quantified using a lutein
and zeaxanthin food frequency questionnaire. Diabetes type, duration, medication, smok-
ing habits, glycosylated hemoglobin (HbA1C), and serum lipid levels were recorded,
whereas visual acuity, body mass index, and diabetic retinopathy grade were measured
for each participant.
Results: One-way analysis of variance revealed a statistically significant difference in
body mass index, age, high-density lipoprotein cholesterol and HbA1C between the three
groups (P , 0.01 for all). Chi-square analysis revealed a statistically significant difference in
diabetic retinopathy distribution (P , 0.01). None of these variables exhibited a statistically
significant correlation with macular pigment optical density for any study group (P . 0.05
for all). There was no difference in dietary carotenoid intake between groups. Macular
pigment optical density was lower among Type 2 diabetes subjects (0.33 ± 0.21) compared
with Type 1 diabetes (0.49 ± 0.23) and controls (0.48 ± 0.35). General linear model analysis,
including age, body mass index, diabetes duration, diabetic retinopathy status, high-
density lipoprotein cholesterol, and HbA1C as covariates, revealed a statistically significant
effect of diabetes type on macular pigment optical density (F = 2.62; P = 0.04).
Conclusion: Macular pigment optical density was statistically significantly lower in Type
2 diabetes compared with Type 1 diabetes and normal controls. Although body mass index
was higher in the Type 2 diabetes group, the lower macular pigment optical density levels
observed among Type 2 diabetes seem not to be attributable to differences in dietary
carotenoid intake or to the specific presence of diabetes, diabetic control, duration, or
diabetic retinopathy.
RETINA 00:1–9, 2015
Neurodegenerative diseases of the retina such as age-related macular degeneration and diabetic retinop-
athy (DR) are leading causes of worldwide blindness.1
Although the relationship between age-related macular
degeneration and macular pigment optical density
(MPOD) has been widely reported,2,3 only a small num-
ber of studies have focused on MPOD and carotenoid
intake in diabetes mellitus,4,5 a condition similarly
known to cause oxidative damage in the retina.6
Diabetes, a lifelong progressive disease, is the result
of the body’s inability to produce insulin or use insulin
to its full potential and is characterized by high circu-
lating glucose.7 Diabetic retinopathy represents the
most common diabetic eye disease, and there is strong
evidence that oxidative stress plays an important role
in its development.6,7 Chronic hyperglycemia causes
oxidative stress,7 which results in microvascular com-
plications at the retina, where the neuronal elements
1
responsible for vision are located. The relationship
between hyperglycemia, changes in redox homeosta-
sis, and oxidative stress are key events in the patho-
genesis of DR.7 Oxidative stress is also involved in the
initiation and progression of obesity and diabetes mel-
litus.8 The links between Type 2 diabetes and obesity
are firmly established.9 Type 2 diabetes now also af-
fects a much younger population because of sedentary
lifestyles and increases in calorific intake and accounts
for more than 90% of all cases of diabetes.10
The development of ocular complications in diabe-
tes is related to disease control and longevity.11–13
After 20 years with diabetes, 75% of patients will have
some form of DR.12 Apart from good systemic control
of blood sugar levels, hypertension, lipid profiles, and
renal function, current treatment modalities for DR are
limited to laser photocoagulation13 and/or intravitreal
injections.14 These are effective modes of treatment
but they also have their own limitations and side ef-
fects. New modalities should, therefore, be preventa-
tive in nature and ideally implemented long before
overt clinical symptoms develop.
Macular pigment is believed to possess antioxidant
properties and to limit retinal oxidative damage by
absorbing harmful short-wavelength blue light.15 Mac-
ular pigment is highly concentrated at the central mac-
ula and is composed of the dietary hydroxycarotenoids
lutein, zeaxanthin, and meso-zeaxanthin.16 These hy-
droxycarotenoids are found in the retina to the exclu-
sion of all other 600 carotenoids found in nature.17
Concentrations of carotenoids in human serum and
deposition of the macular carotenoids in the retina to
form MP are highly variable and reflect not only dietary
intake but also factors such as carotenoid chemistry,18
individual efficacy of absorption,19 fat intake,20 compe-
tition among carotenoids for absorption,21 cholesterol
and lipoprotein status,22,23 metabolic status,4 body com-
position, and body fat/body mass index (BMI).21,24
The relationship between MP and diabetes is only
now attracting research interest, possibly as a result of
the outcomes of clinical trials, which demonstrate
a protective effect of lutein and zeaxanthin supple-
mentation in another oxidative stress-related condition,
age-related macular degeneration.2,3 One experimental
study on diabetic rats demonstrated a reduction in ret-
inal oxidative damage after carotenoid supplementa-
tion.25 Lutein and zeaxanthin intake has also been
shown to improve macular edema in DR patients.5
These results suggest that MP supplementation has
the potential to inhibit or delay the development of
macular disease in patients with diabetes.
This study was designed to investigate the cross-
sectional relationship, if any, between diabetes and
central MPOD and to explore the influence of potential
explanatory factors, including glycosylated hemoglo-
bin (HbA1C), serum lipid levels, BMI, and dietary
carotenoid intake on any relationship that might be
observed.
Materials and Methods
Diabetic and normal control subjects were recruited
for this cross-sectional, case–control study at the Mater
Misericordiae University Hospital in Dublin, Ireland.
The study was approved by the Institutional Research
Ethics Committee and adhered to the tenets of the Dec-
laration of Helsinki. Informed consent was obtained
from all subjects before enrollment and examination.
Generic inclusion criteria were as follows: subjects
were to be older than 18 years, not having taken dietary
supplements containing lutein, zeaxanthin or meso-
zeaxanthin over the 6-month period before the study,
and logMAR visual acuity better than 0.2 (6/9) in the
study eye. For normal (control) subjects, exclusion
criteria included any sign of retinal or ocular abnor-
mality and the presence of Type 1 or Type 2 diabetes.
Patients with diabetes were excluded if they exhibited
signs of ocular comorbidity (e.g., glaucoma, cataract,
age-related macular degeneration), had previously
undergone any form of treatment for DR or maculop-
athy, or if they exhibited any signs of proliferative
retinopathy or maculopathy. The study eye was selected
using the eye with better visual acuity, or, in cases of
equal acuity, the right eye was selected as standard.
Subjects were assigned into one of three study
groups on the basis of their ocular health status and
diabetes type as follows: Group 1: nondiabetic con-
trols; Group 2: Type 1 diabetes; Group 3: Type 2
diabetes. The following diabetes-related information
was recorded for each diabetic participant: diabetes
duration (in years); diabetes type; DR grade (graded
according to modified 2-field Early Treatment Diabetic
Retinopathy Study protocol-grade range R0 M0 to R2
M0), and diabetes medication. Demographic informa-
tion, including age, gender, and history of smoking
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(current smoker, exsmoker, and never smoker), was
collected in relation to each subject.
Procedures
Macular pigment absorbs blue light and is optically
undetectable at 6° to 8° eccentricity.26 In this study,
MPOD was determined using the Macular Metrics
Clinical Densitometer (Macular Metrics, Rehoboth,
MA), which is based on the principle of heterochro-
matic flicker photometry.27 The basic measurement
procedure involves presenting a small test stimulus
that alternates between a measuring wavelength
(458 nm), which is absorbed by macular pigment
and a reference wavelength (540 nm) not absorbed
by the pigment. The subject adjusts the intensity of
the measuring wavelength (458 nm) luminance until
there is minimum flicker (matching luminance). The
luminance of the reference wavelength (540 nm) re-
mains constant. The ratio of the amount of measuring
wavelength (458 nm) light required to achieve the end
point of matching luminance, or minimum flicker, for
foveal and parafoveal readings is a measure of the
amount of pigment present, and the logarithm of this
ratio represents the optical density of MP.
Before using the Densitometer, all subjects were
shown an explanatory video describing the method for
recording null flicker matches. The measurement was
conducted by a trained examiner, and all subjects were
naive to the heterochromatic flicker photometry test.
The MPOD measurement comprised the average of six
readings (computed as the radiance value at which the
subject reported null flicker) taken centrally at 0.5°
retinal eccentricity and again at 0.7° retinal eccentric-
ity. The target used for measuring MPOD at 0.5°
eccentricity was a solid disc of 0.5° arc radius, and
the parafoveal measurement was taken by asking the
subject to fixate on a red light located precisely at 7°
from central fixation. Measurements were deemed reli-
able and acceptable only when the standard deviation
of null flicker responses was below 0.1.
A customized heterochromatic flicker photometry
procedure was adopted, whereby flicker frequency was
optimized for each participant before measurement of
MPOD.28 The starting flicker was set at 10 Hz to 11
Hz. If the subject was unable to find no/minimum
flicker, this frequency was increased until no/minimal
flicker could be identified. If the null one was too
wide, the flicker frequency was reduced. The flicker
frequency was adjusted till the subject found a narrow
null zone.
Dietary carotenoid intake was estimated using the
lutein/zeaxanthin questionnaire (Carotenoid & Health
Laboratory, Jean Mayer USDA Human Nutrition
Center on Aging, Tufts University, USA).29 Body
weight was measured to the nearest 0.2 kg using a Seca
Compact Digital Floor Scale 111, model 888 (Seca
Limited), whereas height was measured to the nearest
0.5 cm using a collapsible “Leicester Height Measure”
stadiometer (CMS Weighing Equipment). Body mass
index was given as weight (in kilograms)/height (in
square meters). Diabetes duration (in years), diabetes
type, and laboratory results including HbA1C and
serum lipid (high-density lipoprotein [HDL], low-
density lipoprotein, total cholesterol, and triglycerides)
levels of patients with diabetes were recorded for each
subject.
Statistical Analysis
The statistical software package SPSS for Microsoft
Windows (v.21.0; IBM Corp., Armonk, NY) was used
for analysis. Data are presented as mean ± standard
deviation throughout. The data were tested for normal-
ity using the Kolmogorov–Smirnov test. One-way anal-
ysis of variance was used to test for differences in
normally distributed study parameters between groups,
whereas the Kruskal–Wallis test was used to test for
differences in group medians in nonnormally distrib-
uted data. The chi-square test was used to compare
categorical data across the three study groups. Pearson’s
product–moment correlation tests were performed to
assess the relationship between MPOD and other study
variables where appropriate. A general linear model
approach was used to explore the relationship between
diabetes type, other potential explanatory variables, and
the dependent variable, MPOD. The level of statistical
significance was set at the standard P , 0.05.
Results
One hundred and fifty subjects were recruited to the
study and divided into 1 of the 3 study groups on the
basis of their ocular health status and diabetes type, as
follows: Group 1: nondiabetic controls (n = 48; male =
20, female = 28); Group 2: Type 1 diabetes (n = 34;
male = 17, female = 17); Group 3: Type 2 diabetes
(n = 68; male = 43, female = 25).
Kolmogorov–Smirnov analysis revealed that BMI,
total cholesterol, lutein intake, zeaxanthin intake, and
MPOD data were normally distributed (P . 0.05 for
each), whereas all remaining variables exhibited non-
normal distributions. Accordingly, parametric tests
were applied, where relevant, to normally distributed
data, and nonparametric equivalent tests to nonnor-
mally distributed data. A comparison of the demo-
graphic and clinical characteristics of each group is
presented in T1Table 1.
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Post hoc analysis (Tukey test) revealed that MPOD
was statistically significantly lower in Type 2 diabetes
compared with both normal controls (P = 0.02) and
Type 1 diabetes (P = 0.03), whereas the difference in
MPOD between Type 1 diabetes and normal controls
was not statistically significant (P = 0.99). The distri-
bution of MPOD for each of the study groups is pre-
sented inF1 Figure 1.
A general linear model analysis confirmed a signifi-
cant effect of diabetes type on the dependent variable,
MPOD (P = 0.04) but no effect of potentially confound-
ing variables including age, BMI, DR status, HDL cho-
lesterol, or HbA1c on MPOD (P = 0.16–0.74).
The distribution of MPOD according to DR status,
which demonstrated no influence on MPOD in the
general linear model analysis (P = 0.45), is presented
inF2 Figure 2.
Body mass index was statistically significantly higher
in Type 2 diabetes compared with normal controls (P ,
0.01) and Type 1 diabetes (P , 0.01), whereas the dif-
ference in BMI between Type 1 diabetes and normal
controls was not statistically significant (P = 0.75). Body
mass index, however, including controlling for confound-
ing was not statistically significantly correlated with
MPOD (r = 0.08, P = 0.51). The distribution of BMI
for each of the study groups is presented inF3 Figure 3.
Discussion
This study demonstrates that MPOD levels are
significantly lower in Type 2 diabetes, when compared
with Type 1 diabetes, which represents an entirely novel
finding. This observation is significant given that similar
dietary carotenoid intake was observed among the study
groups and in the context of shorter diabetes duration
among the Type 2 diabetes subjects. Similarly, the
presence of nonproliferative DR seems not to influence
MPOD levels, which are, surprisingly, slightly higher
on average in those with retinopathy compared with
those without retinopathy, although lower in both
diabetic groups compared with normal controls.
The study further demonstrates that the MPOD
levels in Type 2 diabetes are significantly lower than
in normal controls, a finding, which is in general
agreement with those of previous investigations that
have explored the relationship between MPOD and
diabetes. It has been shown, for example, that Type 2
diabetic subjects had lower MPOD when compared
with nondiabetic controls, while Type 2 diabetes with
mild nonproliferative retinopathy exhibited similar
MPOD levels to Type 2 diabetes without retinopathy.4
In addition, serum lutein and zeaxanthin concentra-
tions, which have been shown to be positively and
significantly related to MPOD in normal subjects,30
have been shown to be significantly lower in diabetes
compared with normal subjects.5 In more advanced
cases of diabetic eye disease, subjects with Grade 2
maculopathy were found to have significantly lower
MPOD than those without maculopathy.31 The appar-
ent relationship between low MP levels and increasing
severity of maculopathy prompted those study inves-
tigators to implicate oxidative stress as a causative
factor, a concept that merits further discussion here.31
Table 1. Demographic and Clinical Findings According to Classification GroupAU7
Normal Controls Type 1 Diabetes Type 2 Diabetes P
Sex 0.07*
Male 20 17 43
Female 28 17 25
Age, years 52.48 ± 16.03 43.67 ± 12.98 62.67 ± 11.31 ,0.01†
BMI, kg/m2 27.7 ± 4.8 27.33 ± 4.77 31.44 ± 6.16 ,0.01‡
Smoking duration 2.13 years 2.35 ± 0.60 2.25 ± 0.65 0.33†
DM duration, years — 22.73 ± 10.85 9.54 ± 7.33 ,0.01†
HbA1c — 7.9 ± 1.08 6.88 ± 1.09 ,0.01†
Triglycerides, mg/dL — 1.37 ± 2.06 1.55 ± 0.85 0.55†
HDL, mg/dL — 1.52 ± 0.46 1.14 ± 0.28 ,0.01†
LDL, mg/dL — 2.37 ± 0.70 2.20 ± 0.74 0.15†
Total cholesterol mg/dL — 4.31 ± 0.82 4.03 ± 0.89 0.14‡
MPOD 0.48 ± 0.35 0.49 ± 0.23 0.33 ± 0.21 ,0.01‡
Lutein intake, mg/day 0.95 ± 0.21 1.06 ± 1.29 0.95 ± 1.73 0.93‡
Zeaxanthin intake, mg/day 0.11 ± 0.12 0.16 ± 0.26 0.12 ± 0.25 0.54‡
Total lutein and zeaxanthin intake, mg/day 1.07 ± 1.25 1.23 ± 1.34 1.07 ± 1.83 0.88‡
Nonproliferative DR — Yes = 23 (68%) Yes = 24 (35%) ,0.01*
No = 11 (32%) No = 44 (65%)
*Chi-square test.
†Kruskal–Wallis test.
‡One-way analysis of variance.
ANOVA, one-way analysis of variance; DM, diabetes mellitus; HbA1c, glycosylated hemoglobin level; LDL, low-density lipoprotein.
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Macular pigment optical density has a slow biological
turnover, as it reflects the local balance between pro-
oxidant stresses and antioxidant defenses in the retina.30
The retina is particularly susceptible to oxidative stress
because of its high oxygen consumption, high propor-
tion of polyunsaturated fatty acids, and exposure to
visible and short-wavelength blue light.32 There is also
considerable evidence that hyperglycemia results in the
generation of reactive oxygen species, ultimately lead-
ing to increased oxidative stress in the retina,6,7 which
may play an important role in the etiology of diabetic
complications. Poor metabolic control and longer dura-
tion of diabetes are directly linked to the prevalence of
DR,11 whereas oxidative stress can be significantly
reduced with aggressive control of hyperglycemia.33
We found no association, however, between MPOD
and either HbA1c or diabetes duration in this study.
Paradoxically, despite their lower MPOD, metabolic
control appeared better, diabetes duration was shorter,
and DR prevalence was lower for Type 2 compared
with Type 1 diabetic subjects. Although HbA1c has
previously been shown to be inversely and significantly
related to MPOD among a smaller sample of Type 2
diabetic subjects,4 our findings imply that lower MPOD
in Type 2 diabetes is not attributable to the diabetic
condition, duration, or level of control, and suggests
a need to explore alternative explanatory causes.
Although BMI measures do not provide a precise
indicator of adiposity, it is likely that the statistically
significantly higher BMI levels observed in the Type 2
diabetes group here, which averaged above WHO-
defined BMI levels indicative of obesity (BMI .
30),34 are reflective of excess adiposity in this group
compared with the normal control and Type 1 diabetes
groups. To date, there has been very little consensus
on the relationship between types of obesity and
MPOD. One study reported a lack of an association
between MPOD and various obesity indices, including
waist circumference, waist-to-hip ratio, and BMI, in
a South-Indian population.35 Conversely, other studies
have shown significant inverse relationships between
body fat and MPOD in humans20,21,24; however, these
relationships differed between men20 and women.21
Lutein and zeaxanthin are known to accumulate in
adipose tissue,36 and lower MPOD values have also
been reported among individuals exhibiting body fat
measuring greater than 27%, when compared with
those with lower body fat.24 Higher body fat percent-
age even within relatively healthy limits is associated
with lower tissue lutein and zeaxanthin status37 and
renders the macular carotenoids less available to reti-
nal tissue.38 Distribution of body fat in the body is also
important, and it has been shown that lutein/zeaxan-
thin concentrations in adipose tissue differ according
Fig. 1. Macular pigment optical
density distribution (mean ± 95%
confidence intervals) according to
diabetes status, illustrating the
substantially lower MPOD levels
among Type 2 diabetic subjects.
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to body site, with levels demonstrably higher in
abdominal fat than in the gluteofemoral fat depot.39
Interestingly, abdominal obesity is now considered
an important risk factor and predictive indicator for
the development of Type 2 diabetes and cardiovascu-
lar disease.40 Waist-to-heightAU5 ratio has more recently
been shown to have superior discriminatory power for
detecting cardiovascular risk factors in both sexes41
and should be considered as a screening tool for dia-
betes, hypertension, and CVD in men and women.41
Future studies investigating the link between MPOD
and obesity should, therefore, encompass more refined
methods of body fat assessment including bioelectrical
impedance analysis and waist-to-height ratio41 because
BMI measurements alone may not be adequate to pro-
vide a true indication of adiposity, and this could
explain the lack of an association between MPOD
and BMI in our study.
Diets, which are high in fat and low in carotenoids,
have been linked with increased oxidative stress.42
Obesity is also independently associated with
increased oxidative stress,42–44 and an increased BMI
has also been shown to be associated with increased
risk of DNA damage due to oxidative stress.45 Serum
8-hydroxy 20-deoxy-guanosine (8-OhdG), for exam-
ple, a known sensitive marker of oxidative DNA dam-
age and of total systemic oxidative stress in vivo, has
been shown to be positively correlated with BMI in
people with Type 2 diabetes mellitus.46
Adipose tissue produces bioactive substances called
adipokines, which induce the production of reactive
oxygen species by a combination of mechanisms
including mitochondrial and peroxisomal oxidation of
fatty acids and overconsumption of oxygen,43,44
thereby initiate a process of oxidative stress43,44 Recent
studies have highlighted the role of increased abdomi-
nal fat mass as a key driver of inflammation in Type 2
diabetes,47 a state closely associated with increased oxi-
dative stress43,44 and macrovascular disease.47 Chronic
inflammation induces changes in metabolic pathways
and is believed to play a significant role in the progres-
sion from obesity to Type 2 diabetes.48,49
Despite the lack of any direct association between
BMI and MPOD observed herein, it is plausible to
suggest that 1) more refined methods of body fat
assessment such as bioelectrical impedance analysis 50
and waist-to-height ratio41 might reveal an association
that could explain the lower MPOD values observed in
Type 2 diabetic subjects here and 2) that the combined
effect of increased competition for lutein/zeaxanthin
deposition and increased inflammation and oxidative
stress levels in association with higher BMI/body fat,
might explain, at least in part, the lower MPOD levels
observed in the Type 2 diabetes group.
Fig. 2. The distribution of
MPOD (mean ± 95% confi-
dence intervals) according to
DR status is illustrated. There is
no significant difference in
MPOD between patients with or
without retinopathy indicating
that retinopathy status seems
not to be the main driver in
influencing MP levels.
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High-density lipoprotein differences observed
between Type 1 and Type 2 diabetes could also
contribute to the lower MP levels observed in the Type
2 diabetes group. Macular pigment carotenoids are
primarily transported by HDL in plasma.22,23 It has
been suggested that mechanisms governing the retinal
capture and/or stabilization of these carotenoids in the
retina may be subject to HDL influence, by affecting
receptor-mediated uptake of these carotenoids from
serum.23 High-density lipoprotein deficiencies are asso-
ciated with lutein and zeaxanthin tissue deficiencies,
most notably in the retina.22 Furthermore, it has been
suggested that individuals exhibiting elevated serum tri-
glyceride concentrations and concurrently reduced
serum HDL concentrations may have a related and
reduced capacity to transport lutein in serum.23 Such
features are very characteristic of Type 2 but not Type
1 diabetes.51 Lipoprotein profile is adversely affected
by insulin resistance and might mechanistically explain
(by eliciting a reduced capacity to transport macular
carotenoids), why Type 2 diabetes is associated with
lower MP levels compared with Type 1 diabetes where
insulin resistance is much less prominent. A more com-
prehensive investigation into the association between
lipoprotein profile, MPOD, and dietary carotenoid
intake among diabetic subjects is therefore warranted.
Average macular carotenoid intake was similar for
the three study groups (P = 0.88) and at levels that are
consistent with the lower limits of average daily carot-
enoid intake, (ranges from 1.1 to 1.6 mg/day).30
Although dietary intake is the primary driver of tissue
carotenoid levels,15 the relationship between diet and
deposition of these pigments in the retina is moderated
by a number of factors. Retinal capture and/or stabili-
zation of these carotenoids in the macula, may, for
example, be subject to influence by obesity-induced
inflammation and oxidative stress,48,49 competition
between adipose and retinal tissue for the dietary car-
otenoids,21,24,37 impaired transport of circulating
lutein/zeaxanthin,22,23 and/or genetic influence,52
which may help to explain the significant effect of
Type 2 diabetes on MPOD.
Limitations to this cross-sectional case control study
include the use of a dietary questionnaire designed for
an American population among European participants,
lack of serum carotenoid analysis, lack of detailed
body fat analysis, and the absence of other clinical
parameters such as inflammatory markers. Further
research is needed in the diabetic population to
uncover the relationship between disease progression,
BMI including waist-to-height ratio, body fat compo-
sition, serum cholesterol, inflammatory status, and
dietary carotenoid intake, as well as the mechanism
of retinal damage in the presence of low MPOD. The
effects of the adiposity, insulin resistance, inflamma-
tion, and HDL suppression characteristics that
Fig. 3. Body mass index dis-
tribution (mean ± 95% confi-
dence intervals) according to
diabetes status, illustrating sub-
stantially higher BMI levels
among Type 2 diabetic subjects.
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differentiate Type 2 from Type 1 diabetes on MPOD
should be particularly emphasized.
A longitudinal study, comparing MPOD in Type 1
and Type 2 diabetes with parameters such as lipoprotein
profile (including low-density lipoprotein, HDL, and
triglycerides),22,23 obesity indices (including waist-to-
height, bioelectrical impedance analysis, BMI, waist
circumference, and waist-to-hip measurements),41 and
dietary intake of lutein and zeaxanthin,31 would certainly
provide a more holistic understanding of the relationship
between MPOD and BMI in Type 2 diabetic patients
over time. Certain features such as obesity,8 low HDL,
and raised triglycerides are characteristic of Type 2 but
not Type 1 diabetes,51 and these characteristics may
indeed affect the transport, uptake, and stabilization of
these carotenoids in the retina and would, therefore,
warrant further investigation.
Key words: customized heterochromatic flicker
photometry, diabetes mellitus, diabetic retinopathy,
glycosylated hemoglobin, lutein, macular pigment
optical density, meso-zeaxanthin, zeaxanthin.
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